Klimadynon Reviews

Klimadynon is a dietary supplement that utilizes the healing power of botanicals to provide relief to the different symptoms of menopause. It is formulated to be a safer alternative to hormone replacement therapy (HRT) which is the gold standard in treating menopause symptoms.

The formulation is from Bionorica which is a company based in Germany. They offer several dietary supplements but the company still has not established a reputation in the health, wellness and supplement industries.

One box which contains 90 tablets is priced $12 online but shipping charges will apply since the product will be shipped from Germany.


Overview Of Klimadynon

While menopause is a natural process, it may come with various uncomfortable physical symptoms, including hot flashes. Its emotional symptoms are sleep disruptions, low energy levels, among others.

In many cases, medical remedies might not be needed to relieve menopause symptoms as various supplements on the market might serve the purpose. Klimadynon tablets are amongst the supplements that claim to relieve menopause symptoms.

This dietary supplement claims to use various botanicals to reduce sweating at night, fight hot flashes, and enhance one’s mental wellness.

Reading through Klimadynon Reviews, you may get an impression of a working supplement. Even so, it is always judicious to carry out in-depth research about a supplement before using it, and our review may serve this purpose.

Klimadynon® in Comparison to Conjugated Oestrogens in Women Suffering From Menopausal Complaints

Condition or disease Intervention/treatment Phase
Menopause Drug: Low dose of Klimadynon® Drug: Medium dose of Klimadynon® Drug: High dose of Klimadynon® Drug: Oestrofeminal® Drug: Placebo Phase 3

Layout table for study information

Study Type :Interventional (Clinical Trial)Actual Enrollment :161 participantsAllocation:RandomizedIntervention Model:Parallel AssignmentMasking:DoublePrimary Purpose:TreatmentOfficial Title:Double-blind Dose/Response Study Comparing Klimadynon® With Conjugated Oestrogens in Women Suffering From Menopausal ComplaintsStudy Start Date :November 1998Actual Primary Completion Date :September 2000

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Low dose of Klimadynon® Drug: Low dose of Klimadynon®
Experimental: Medium dose of Klimadynon® Drug: Medium dose of Klimadynon®
Experimental: High dose of Klimadynon® Drug: High dose of Klimadynon®
Active Comparator: Oestrofeminal® Drug: Oestrofeminal®
Placebo Comparator: Placebo Drug: Placebo
  1. Change of score in menopause-related symptom categories of the modified menopausal rating scale (MRS) [ Time Frame: baseline, week 12 ]
  2. Change of score of MRS items 7-10 and items 1-10 [ Time Frame: baseline, week 12 ]
  3. Change of menopause index according to Kupperman [ Time Frame: Baseline up to day 98 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information,

Layout table for eligibility information

Ages Eligible for Study: 40 Years to 60 Years (Adult)
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: No
  • Only postmenopausal (amenorrhea for 6 months at least) women may be enrolled in the study
  • Women after ovariectomy may also be enrolled if surgery was carried out at least 6 months prior to the enrollment. Only women between the age of 40 and 60 may be included

2 weeks (control -1, week -2, day -14) before the beginning of the treatment the following hormone values must have been analyzed:

  • estradiol-17ß ≤ 0.15 nmol/l corresponding to ≤ 40 pg/ml and follicle stimulating hormone (FSH) ≥ 25 milliunits per milliliter (mU/ml)
  • These hormone analyses must be carried out at the competent local laboratory

In addition to other menopausal complaints the women must have hot flushes / outbreaks of sweating:

  • Diary: During the “run-in period” daily ≥ 3 hot flushes / outbreaks of sweating
  • Modified Menopause Rating Scale, 1st item twofold (week -2 and 0) ≥ 0.3

General criteria for exclusion:

  • Non-responder (= no therapeutic success) under a pretreatment with estrogen
  • Amenorrhea for < 6 months
  • In case of an estrogen pretreatment last menstruation (menopause) > 3 years earlier
  • Sum score of the modified Menopause Rating Scale (items 1 – 6) during the “run-in period” twice (week -2 and 0) < 1.7
  • No hot flushes / outbreaks of sweating (see Inclusion criteria)
  • At one of the appointments of the “run-in period” (week -2 and 0) more than one question of items 1 – 6 of the modified Menopause Rating Scale (MMRS) not answered
  • During the “run-in period” at the appointment week -2: estradiol-17ß > 40 pg/ml corresponding to > 0.15 nmol/l and FSH < 25 mU/ml
  • Condition after hysterectomy
  • Simultaneous ingestion of estrogen-containing products in addition to the test products
  • Any addition ingestion of psychotropic drugs, antidepressants and sleeping aids (hypnotics / sedatives)
  • Treatment with another study drug in the 2 months preceding the beginning of the study
  • Considerable overweight (exceeding the target body weight [height in cm minus 100] by more than 30%)
  • Poor general condition
  • Alcohol or drug abuse
  • Poor compliance

Exclusion criteria based on conjugated estrogens or medroxyprogesterone:

  • Any contraindication for estrogen
  • Unresolved genital bleeding
  • Suspicion / existence of estrogen-dependent mammary carcinoma (mammography and/or endometrial carcinoma)
  • Endometriosis
  • Endometrial hyperplasia (including hyperplastic polypoid endometrium, which has not yet reached the stage of a glandular cystic hyperplasia)
  • Thickness of endometrium > 5 mm
  • Existing thromboembolism or thromboembolism in the past
  • Phlebitis in the past 2 years or actually existing
  • Acute or chronic hepatic lesion (aspartate transaminase and/or alanine transaminase and/or gamma glutamyl transferase twice the normal range)
  • Metabolic disorders of bile pigments (Dubin-Johnson’s syndrome, Rotor syndrome, pregnancy icterus with/without pruritus in previous pregnancy)
  • Sickle cell anemia
  • Clinically relevant hypertriglyceridemia or hypercholesterolemia
  • Heart attack in the past
  • Severe varicosis
  • Known sensitivity to medroxyprogesterone
  • Case history of anaphylactic reaction
  • Any neoplasm at the genitals
  • Case history of antidepressant treatment
  • Diabetes mellitus with or without treatment

Muscle damage has been attributed to black cohosh [ 20 ].

Klimadynon 2.8 mg tabletės, N90 usage

Visada vartokite Klimadynon tabletes tiksliai kaip nurodė gydytojas arba vaistininkas. Jeigu abejojate, kreipkitės į gydytoją arba vaistininką.

Rekomenduojama dozė yra:
Įprastinė dozė suaugusioms moterims, kurioms pasireiškia menopauzė, yra: 1 Klimadynon tabletė du kartus per parą (ryte ir vakare). Daugiausiai galima vartoti 2 Klimadynon tabletes per parą.

Vartojimo metodas
Vartoti per burną. Tabletę nuryti, užgeriant trupučiu skysčio. Nekramtykite ir nečiulpkite tablečių.

Vartojimo trukmė

  • Jeigu simptomai tęsiasi vaistinio preparato vartojimo metu, reikia pasitarti su gydytoju arba vaistininku.
  • Klimadynon be gydytojo leidimo negalima vartoti ilgiau kaip 6 mėnesius.